Zepatier was effective and well-tolerated in black patients with hepatitis C genotype 1 and 4 compared with overall reported safety profile, according to recently published data.
“The results from this retrospective analysis of clinical trial data support the use of [elbasvir/grazoprevir (EBR/GZR)] in black individuals with HCV… infection,” Zamor wrote. “EBR/GZR showed high efficacy across many subgroups of black participants, including those with cirrhosis, [chronic kidney disease], HIV co-infection, or sickle cell disease, as well as those taking opioid agonist therapy, and was generally well tolerated, with a safety profile similar to that reported in the general population of participants in the EBR/GZR clinical trials.”
Zamor and colleagues gathered patient data from nine international phase 2/3 studies, including 317 black patients who received Zepatier (elbasvir/grazoprevir, Merck) for 12 weeks, 15 black patients who received elbasvir/grazoprevir with ribavirin for 16 weeks, and 1,310 nonblack participants who received 12 weeks of elbasvir/grazoprevir for comparison.
March 15 (UPI) — An eight-week treatment regimen for hepatitis C is just as effective as the recommended 12 weeks in African-American patients, according to a Harvard study.
Because of the shorter treatment, patients with the serious liver disease can have their costs reduced, according to a study published this week in Clinical Gastroenterology and Hepatology.
In the United States, an estimated 3.5 million people are living with hepatitis C, according to the Centers for Disease Control and Prevention. But in the African-American community, chronic liver disease and cirrhosis, which often are hepatitis C-related, were among the leading causes of death for people between age 45 and 64.
Although the introduction of direct-acting antivirals (DAAs) transformed the treatment of hepatitis C virus (HCV), significant challenges in managing HCV infection in high-risk populations still remain.
A recent review article pointed out that “African Americans [AAs] in the US are twice as likely to be infected with HCV compared to the non-Hispanic-white US population (3% vs 1.5%).”1 AAs are also more likely to be infected with genotype 1 HCV, less likely to respond well to interferon-based therapies, and more likely to develop HCV-related complications such as hepatocellular carcinoma.1,2
A study examining HCV-associated all-cause mortality in the US population found that the mortality rate of Mexican Americans with chronic HCV was approximately 7 times higher than that in HCV-negative individuals.3 A different study conducted in a cohort on HCV-infected US veterans found that Hispanics with HCV had a significantly higher risk of developing cirrhosis and hepatocellular carcinoma than non-Hispanic whites.4